Wall Street Zen Upgrades Sanofi (NASDAQ:SNY) to Buy

Sanofi (NASDAQ:SNY) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other brokerages have also recently commented on SNY. Weiss Ratings cut Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Morgan Stanley set a $49.00 price objective on Sanofi in a report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Price Performance

NASDAQ:SNY opened at $44.82 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68. The company has a market cap of $108.66 billion, a PE ratio of 23.47, a P/E/G ratio of 1.37 and a beta of 0.35. The company’s 50 day moving average is $43.67 and its two-hundred day moving average is $44.80.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period in the prior year, the business posted $3.24 EPS. Analysts anticipate that Sanofi will post 5.01 EPS for the current year.

Hedge Funds Weigh In On Sanofi

Several institutional investors and hedge funds have recently modified their holdings of the stock. Syon Capital LLC boosted its stake in shares of Sanofi by 22.3% in the second quarter. Syon Capital LLC now owns 6,102 shares of the company’s stock worth $260,000 after buying an additional 1,112 shares during the last quarter. Concurrent Investment Advisors LLC raised its position in Sanofi by 6.6% during the second quarter. Concurrent Investment Advisors LLC now owns 23,781 shares of the company’s stock valued at $1,014,000 after acquiring an additional 1,471 shares in the last quarter. Natural Investments LLC raised its position in Sanofi by 12.7% during the second quarter. Natural Investments LLC now owns 6,237 shares of the company’s stock valued at $266,000 after acquiring an additional 704 shares in the last quarter. M Holdings Securities Inc. acquired a new position in Sanofi in the second quarter valued at approximately $906,000. Finally, Archer Investment Corp acquired a new position in Sanofi in the second quarter valued at approximately $174,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.